Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
39 hedge funds and large institutions have $220M invested in Kezar Life Sciences in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
14% more capital invested
Capital invested by funds: $194M → $220M (+$26.5M)
5% more funds holding
Funds holding: 37 → 39 (+2)
1.48% more ownership
Funds ownership: 47.38% → 48.86% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$20M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.79M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.37M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.05M |
| 5 |
State Street
Boston,
Massachusetts
|
+$813K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
-$6.67M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.58M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$4.85M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.69M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.18M |
KZR Hedge Fund Activity: Q4 2018 in Review
39 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2018, worth a combined $220M — up 14% from $194M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KZR positions and 7 closed out — a net gain of 3 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $20M. The largest seller was Cowen Inc, cutting an estimated $6.67M.
- 39 institutional investors held Kezar Life Sciences (KZR) as of Q4 2018, up from 37 in Q3 2018.
- Funds reported $220M of Kezar Life Sciences stock for Q4 2018, up 14% quarter-over-quarter.
- 10 funds opened new Kezar Life Sciences positions in Q4 2018 and 7 closed out, a net change of +3 holders.
- The largest Kezar Life Sciences buyer in Q4 2018 was BB Biotech, an estimated $20M added.
- The largest Kezar Life Sciences seller in Q4 2018 was Cowen Inc, an estimated $6.67M sold.
Based on aggregated 13F filings for Q4 2018.